AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ

Cevdet Kaya; Abdullah İlktaç; Mustafa Güneş; Metin Öztürk; Hüseyin Kanberoğlu; Muhammet Karaman

-

Year 2008, Volume: 21 Issue: 2, 127 - 132, 24.06.2015

Cevdet Kaya , Abdullah İlktaç Mustafa Güneş Metin Öztürk Hüseyin Kanberoğlu Muhammet Karaman

Abstract

Keywords

References

Abrams P, Cardozo L, Fall M, et al. The standardization
of terminology of lower urinary tract function: report
from the Standardization Subcommittee of the
International Continence Society. Neurourol Urodyn
: 21: 167-178.
Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J,
Wein AJ. How widespread are the symptoms of an
overactive bladder and how are they managed? A
population based prevalence study. BJU Int 2001: 87:
-766.
Milson I, Stewart W, Thuroff J. The prevalence of
overactive bladder. Am J Manag Care 6 (Suppl. 11)
: S565-5573
Yoshimura N, de Groat WC. Neural control of lower
urinary tract. Int J Urol 1997: 4: 111-125.
De Groat WC. A neurologic basis for the overactive
bladder. Urology suppl. 1997: 50: 36-52.
Wang P, Luthin GR, Ruggieri MR. Muscarinic
acetylcholine receptor subtypes mediating urinary
bladder contractility and coupling to GTP binding
proteins. J Pharmacol Exp Ther 1995: 273: 959-966.
Yoshimura N, Chancellor MB. Current and future
pharmacological treatment for overactive bladder. J Urol
: 168:1897-1913.
Wein AJ. Neuromuscular dysfunction of lower urinary
tract and its management. In: Walsh PC, Retik AB,
Darracot Vaughan jr. E, Wein AJ (eds) Campell’s
Urology. Saunders, Philadelphia, 2002: 931-1026.
Madersbacher H, Rovner E. Trospium chloride: the
European experience. Expert Opin Pharmacother 2006:
:1373-1380.
Hofner K, Oelke M, Machtens S, Grunewald T.
Trospium chloride an effective drug in the treatment of
overactive bladder and detrusor hyperreflexia. World J
Urol 2001: 19: 336-343.
Guay DR. Clinical pharmacokinetics of drugs used to
treat urge incontinence. Clin Pharmacokinet 1986: 42:
-1285.
Vereecken RL. A critical view on the value of
urodynamics in non neurogenic incontinence in women.
Int Urogynecol J 2000: 11: 188-195.
Coyne KS, Zyczynski T, Margolis MK, Elinof V,
Roberts RG. Validation of an overactive bladder
awareness tool for use in primary care settings. Adv
Ther 2005: 22: 381-394.
Hu TW, Wagner TH, Bentkover JD, et al. Estimated
economic cost of overactive bladder in the United
States. Urology 2003: 61: 1123-1128.
Abrams P, Anderson KE. Muscarinic receptor
anragonists for overactive bladder. BTU Int 2007: 100:
-1006.
Zinner M, Gittelman M, Haris R, et al. Trospium
chloride improves bladder symptoms. A multicenter
phase III trial. J Urol 2004:171: 2311-2315.
Rudy D, Cline K, Harris R, et al.Multicenter phase III
trial studying trospium chloride in patients with over
active bladder. Urology 2006; 67:275-280.
Halaska M, Ralph G, Wiedeman A, et al. Controlled,
double-blind, multicenter clinical trial to investigate
long-term tolerability and efficacy of trospium chloride
in patients with detrusor instability. World J Urol 2002:
: 392-399.
Flisser A, Walmsey K, Blavias JG. Urodynamics
classification of patients with symptoms of overactive
bladder. J Urol 2003: 169: 529-533.
Lin LY, Yeh NH, Lin CY, Sheu BC, Lin HH.
Comparisons of urodynamic characteristics between
female patients with overactive bladder and overactive
bladder plus stress urinary incontinence. Urology 2004:
: 945-949.
Digesu GA, Khullar V, Cardozo L, Stefano S.
Overactive bladder symptoms: Do we need
urodynamics? Neurourol Urodyn 2003: 22: 105-108.
Ouslander JG. Management of overactive bladder. N
Engl J Med 2004: 350: 786-799.
Staskin DR, Wein AJ, Andersson KE, et al. Overview
consensus statement. Urology 2003: 61: 1128-8.
Alloussi S, Laval KU, Eckert R, et al. Trospium chloride
in patients with motor urge symptoms: A double blind,
randomised, multicentre, placebo controlled study. J
Drug Asses 1999: 2: 27-39.

AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ

Year 2008, Volume: 21 Issue: 2, 127 - 132, 24.06.2015

Cevdet Kaya , Abdullah İlktaç Mustafa Güneş Metin Öztürk Hüseyin Kanberoğlu Muhammet Karaman

Abstract

Amaç: Aşırı aktif mesane sendromu bulunan kadınlarda trospium tedavisinin etkinliği ve bu etkinin ürodinamik bulgular ile ilişkisi araştırıldı. Yöntem: Aşırı aktif mesane sendromu bulunan 44 kadın hasta çalışmaya alındı. 8 haftalık trospiyum tedavisinden sonra, hastaların tedavi öncesi ve sonrası OAB-V8 semptom skoru, ürodinamik bulguları karşılaştırıldı. Bulgular: Ortalama OAB-V8 semptom skoru tedavi ile birlikte anlamlı olarak düşük bulundu (11.9±6.3; 24.9±5.1; p<0.05).Detrusor aşırı aktivitesi bulunan kadın hastaların (10.3±4.1) detrusor aşırı aktivitesi olmayan kadın hastalara (14.2+5.3) göre trospium tedavisinden daha fazla fayda gördükleri saptandı. Sonuç: Trospium tedavisi ispatlanmış detrusor aşırı aktivitesi olan kadın hastalarda daha etkili bulunmuştur. Anahtar Kelimeler: Aşırı aktif mesane, İşeme disfonksiyonu, Farmakoterapi

Keywords

References

Abrams P, Cardozo L, Fall M, et al. The standardization
of terminology of lower urinary tract function: report
from the Standardization Subcommittee of the
International Continence Society. Neurourol Urodyn
: 21: 167-178.
Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J,
Wein AJ. How widespread are the symptoms of an
overactive bladder and how are they managed? A
population based prevalence study. BJU Int 2001: 87:
-766.
Milson I, Stewart W, Thuroff J. The prevalence of
overactive bladder. Am J Manag Care 6 (Suppl. 11)
: S565-5573
Yoshimura N, de Groat WC. Neural control of lower
urinary tract. Int J Urol 1997: 4: 111-125.
De Groat WC. A neurologic basis for the overactive
bladder. Urology suppl. 1997: 50: 36-52.
Wang P, Luthin GR, Ruggieri MR. Muscarinic
acetylcholine receptor subtypes mediating urinary
bladder contractility and coupling to GTP binding
proteins. J Pharmacol Exp Ther 1995: 273: 959-966.
Yoshimura N, Chancellor MB. Current and future
pharmacological treatment for overactive bladder. J Urol
: 168:1897-1913.
Wein AJ. Neuromuscular dysfunction of lower urinary
tract and its management. In: Walsh PC, Retik AB,
Darracot Vaughan jr. E, Wein AJ (eds) Campell’s
Urology. Saunders, Philadelphia, 2002: 931-1026.
Madersbacher H, Rovner E. Trospium chloride: the
European experience. Expert Opin Pharmacother 2006:
:1373-1380.
Hofner K, Oelke M, Machtens S, Grunewald T.
Trospium chloride an effective drug in the treatment of
overactive bladder and detrusor hyperreflexia. World J
Urol 2001: 19: 336-343.
Guay DR. Clinical pharmacokinetics of drugs used to
treat urge incontinence. Clin Pharmacokinet 1986: 42:
-1285.
Vereecken RL. A critical view on the value of
urodynamics in non neurogenic incontinence in women.
Int Urogynecol J 2000: 11: 188-195.
Coyne KS, Zyczynski T, Margolis MK, Elinof V,
Roberts RG. Validation of an overactive bladder
awareness tool for use in primary care settings. Adv
Ther 2005: 22: 381-394.
Hu TW, Wagner TH, Bentkover JD, et al. Estimated
economic cost of overactive bladder in the United
States. Urology 2003: 61: 1123-1128.
Abrams P, Anderson KE. Muscarinic receptor
anragonists for overactive bladder. BTU Int 2007: 100:
-1006.
Zinner M, Gittelman M, Haris R, et al. Trospium
chloride improves bladder symptoms. A multicenter
phase III trial. J Urol 2004:171: 2311-2315.
Rudy D, Cline K, Harris R, et al.Multicenter phase III
trial studying trospium chloride in patients with over
active bladder. Urology 2006; 67:275-280.
Halaska M, Ralph G, Wiedeman A, et al. Controlled,
double-blind, multicenter clinical trial to investigate
long-term tolerability and efficacy of trospium chloride
in patients with detrusor instability. World J Urol 2002:
: 392-399.
Flisser A, Walmsey K, Blavias JG. Urodynamics
classification of patients with symptoms of overactive
bladder. J Urol 2003: 169: 529-533.
Lin LY, Yeh NH, Lin CY, Sheu BC, Lin HH.
Comparisons of urodynamic characteristics between
female patients with overactive bladder and overactive
bladder plus stress urinary incontinence. Urology 2004:
: 945-949.
Digesu GA, Khullar V, Cardozo L, Stefano S.
Overactive bladder symptoms: Do we need
urodynamics? Neurourol Urodyn 2003: 22: 105-108.
Ouslander JG. Management of overactive bladder. N
Engl J Med 2004: 350: 786-799.
Staskin DR, Wein AJ, Andersson KE, et al. Overview
consensus statement. Urology 2003: 61: 1128-8.
Alloussi S, Laval KU, Eckert R, et al. Trospium chloride
in patients with motor urge symptoms: A double blind,
randomised, multicentre, placebo controlled study. J
Drug Asses 1999: 2: 27-39.

There are 81 citations in total.

Details

Primary Language	Turkish
Journal Section	Articles
Authors	Cevdet Kaya Abdullah İlktaç This is me Mustafa Güneş This is me Metin Öztürk This is me Hüseyin Kanberoğlu This is me Muhammet Karaman This is me
Publication Date	June 24, 2015
Published in Issue	Year 2008 Volume: 21 Issue: 2

Cite

APA	Kaya, C., İlktaç, A., Güneş, M., Öztürk, M., et al. (2015). AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ. Marmara Medical Journal, 21(2), 127-132.
AMA	Kaya C, İlktaç A, Güneş M, Öztürk M, Kanberoğlu H, Karaman M. AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ. Marmara Med J. August 2015;21(2):127-132.
Chicago	Kaya, Cevdet, Abdullah İlktaç, Mustafa Güneş, Metin Öztürk, Hüseyin Kanberoğlu, and Muhammet Karaman. “AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ”. Marmara Medical Journal 21, no. 2 (August 2015): 127-32.
EndNote	Kaya C, İlktaç A, Güneş M, Öztürk M, Kanberoğlu H, Karaman M (August 1, 2015) AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ. Marmara Medical Journal 21 2 127–132.
IEEE	C. Kaya, A. İlktaç, M. Güneş, M. Öztürk, H. Kanberoğlu, and M. Karaman, “AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ”, Marmara Med J, vol. 21, no. 2, pp. 127–132, 2015.
ISNAD	Kaya, Cevdet et al. “AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ”. Marmara Medical Journal 21/2 (August 2015), 127-132.
JAMA	Kaya C, İlktaç A, Güneş M, Öztürk M, Kanberoğlu H, Karaman M. AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ. Marmara Med J. 2015;21:127–132.
MLA	Kaya, Cevdet et al. “AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ”. Marmara Medical Journal, vol. 21, no. 2, 2015, pp. 127-32.
Vancouver	Kaya C, İlktaç A, Güneş M, Öztürk M, Kanberoğlu H, Karaman M. AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ. Marmara Med J. 2015;21(2):127-32.